Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club
Drug Research
Return to: PBR Home | Drug Research
Today in Drug Research

Drug Research

Novartis-Genentech's Urticaria drug Xolair gets US FDA approval The US Food and Drug Administration (FDA) has approved Novartis and Genentech's Xolair (omalizumab) for the treatment of chronic idiopathic urticaria (CIU), an unpredictable and debilitating skin disease that is called as chronic spontaneous urticaria (CSU) outside of the US. Drug Research > Drug Delivery > News

Latest Drug Research News by Sector

Select a sector from the list or browse by sector below:

Drug Delivery

Astellas Pharma reaches agreement with US Department of Justice
17 April 2014
Astellas Pharma US has reached an agreement with the US Department of Justice to resolve civil claims regarding the marketing of Mycamine (micafungin sodium) for injection.
Drug Research > Drug Delivery > News
European Medicines Agency alerts EU healthcare professionals after vials of falsified Herceptin identified
17 April 2014
The European Medicines Agency (EMA) has been informed that vials of the cancer medicine Herceptin (trastuzumab), thought to have been stolen in Italy, including from hospitals, have been tampered with and re-introduced under false credentials into the supply chain in some countries.
Drug Research > Drug Delivery > News

Drug Discovery & Development

Islet Sciences reports results from two Phase IIb clinical studies for type 2 diabetics drug
17 April 2014 | By PBR Staff Writer
Islet Sciences and BHV Pharma have reported positive data from the two 12-week Phase IIb clinical studies of SGLT2 inhibitor remogliflozin etabonate in type 2 diabetics.
Drug Research > Drug Discovery & Development > News
OxThera secures $10m investment to continue clinical programs
17 April 2014 | By PBR Staff Writer
Swedish biopharmaceutical firm OxThera has received SEK70m ($10m) from a syndicate of new investors, led by Kurma Partners, including IdInvest Partners and Mayo Clinic, to continue its major clinical programs.
Drug Research > Drug Discovery & Development > News